Alnylam Pharmaceuticals
ALNY
#448
Rank
S$67.44 B
Marketcap
S$510.51
Share price
-2.68%
Change (1 day)
55.48%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): S$0.15 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$3.21 Billion. In 2024 the company made an earning of -S$0.31 Billion, an increase over its 2023 earnings that were of -S$0.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) S$0.15 B-151.88%
2024 -S$0.31 Billion-24.59%
2023 -S$0.41 Billion-67.84%
2022 -S$1.25 Billion36.93%
2021 -S$0.92 Billion-8.04%
2020 -S$1 Billion-15.66%
2019 -S$1.18 Billion12.23%
2018 -S$1.05 Billion62.91%
2017 -S$0.65 Billion17.78%
2016 -S$0.55 Billion43.44%
2015 -S$0.39 Billion60.69%
2014 -S$0.24 Billion98.2%
2013 -S$0.12 Billion
2011 -S$70.53 Million27.48%
2010 -S$55.33 Million-10.92%
2009 -S$62.11 Million95.77%
2008 -S$31.73 Million
2006 -S$50.82 Million-9.13%
2005 -S$55.93 Million34.74%
2004 -S$41.51 Million36.79%
2003 -S$30.35 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
S$0.18 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
S$6.61 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-S$0.33 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-S$0.21 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-S$61.02 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
S$21.12 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$11.70 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
S$2.27 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel